The FDA’s draft guidance outlines a framework for assessing AI models in drug development, emphasizing model credibility, risk assessment, and compliance with privacy and ethical standards, while inviting public comments until April 7, 2025.
View full story…
FDA Releases Draft Guidance on AI Integration in Drug Development
